Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 62.54M | 56.76M | 56.01M | 50.11M | 45.48M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 263.46M | 250.64M | 230.86M | 209.10M | 188.19M |
Operating Income | -263.46M | -250.64M | -230.86M | -209.10M | -188.19M |
Income Before Tax | -243.61M | -293.25M | -273.79M | -253.75M | -235.66M |
Income Tax Expenses | 178.00K | 446.00K | 393.00K | 268.00K | 268.00K |
Earnings from Continuing Operations | -243.79 | -293.70 | -274.18 | -254.02 | -235.93 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -243.79M | -293.70M | -274.18M | -254.02M | -235.93M |
EBIT | -263.46M | -250.64M | -230.86M | -209.10M | -188.19M |
EBITDA | -262.83M | -250.00M | -230.20M | -208.43M | -187.53M |
EPS Basic | -1.53 | -1.88 | -2.56 | -3.47 | -4.34 |
Normalized Basic EPS | -0.96 | -0.91 | -1.33 | -1.90 | -2.45 |
EPS Diluted | -1.53 | -1.88 | -2.56 | -3.47 | -4.34 |
Normalized Diluted EPS | -0.96 | -0.91 | -1.33 | -1.90 | -2.45 |
Average Basic Shares Outstanding | 637.49M | 629.34M | 516.45M | 387.59M | 258.93M |
Average Diluted Shares Outstanding | 637.49M | 629.34M | 516.45M | 387.59M | 258.93M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |